Next Generation Gynecological Cancer Diagnostic Market Overview
The Global Next Generation Gynecological Cancer Diagnostic Market size is expected to grow from USD 2.67 billion in 2023 to USD 6.67 billion by 2032, at a CAGR of 10.70% during the forecast period (2024-2032).
Cancer that originates in a woman's reproductive organs is referred to as gynecologic cancer. Cancer is always named after the body part where it first appears. Gynecologic cancers can start anywhere in a woman's pelvis, which is the area beneath the stomach and between hip bones. Cervical, ovarian, uterine, vaginal, and vulvar cancers are several types of gynecologic cancer. Ovarian cancer is the most common gynecologic cancer.
Advancement in technology has resulted in the development of innovative techniques for the diagnosis of gynecologic cancer such as quantitative polymerase chain reaction (qPCR) & multiplexing, next-generation sequencing, and lab-on-a-chip (LOAC) & reverse transcription-polymerase chain reaction (RT-PCR), and microarray. Advancements in the technologies of sequencing have supported researchers, and clinics to get knowledge which further helped to discover biomarkers for guidance. According to WHO, cancer is the leading cause of death across the globe, with approximately 10 million deaths in 2020. In the same year, about 342,000 women died due to cervical cancer. The growing prevalence of cervical cancer and the supportive government initiatives to prevent fatalities is expected to support the development of the next generation of gynecological cancer diagnostic over the forecasted timeframe.
Market Dynamics And Factors Next Generation Gynecological Cancer Diagnostic Market
Drivers:
Growing Prevalence of Cervical & Ovarian Cancer
The increase in the number of gynecological cancer cases is the main factor stimulating the development of next-generation gynecological cancer diagnoses during the analysis period. Breast cancer is the most common cancer diagnosed in women worldwide, whereas, with an estimated 604,000 new cases in 2020, cervical cancer is the fourth most common cancer in women. Around 90% of the estimated 342,000 cervical cancer deaths in 2020 will occur in low- and middle-income countries. HIV-positive women are six times more likely than HIV-negative women to acquire cervical cancer, with HIV accounting for about 5% of all cervical cancer cases. Furthermore, HIV contributes disproportionately to cervical cancer in younger women in all world regions.
Ovaries are a part of the female reproductive system, and ovarian cancer occurs when abnormal cells in the ovary begin to proliferate and divide uncontrollably. The most frequent kind of ovarian cancer is epithelial ovarian cancer. Primary peritoneal cancer and fallopian tube cancer are both treated the same way as epithelial ovarian cancer. Germ cell tumors (teratomas and dysgerminomas), stromal tumors (granulosa tumors), and sarcomas are all rare kinds of ovarian cancer. According to a WHO report, 314,000 females were diagnosed with ovarian cancer in 2020, and this number is expected to reach 429,000 by 2040. The fatalities were 207,000 in 2020 which is anticipated to reach 306,000 by 2040. Thus, the growing cases of ovarian and cervical cancer are expected to boost the expansion of the next-generation gynecological cancer diagnostic market over the analysis period.
Restraints:
Low Funding and Restricted Usage of Innovative Diagnostics Techniques
Techniques involved in next-generation cancer diagnostics are new to the world, and there is a need for more research to validate their effectiveness in diagnostic procedures. Next-Generation Sequencing techniques are Laboratory Developed Tests (LDTs). There are very few laboratories that offer NGS for diagnostics as a skilled labor force is required. Regulatory policies regarding the development and usage of NGS are very strict. In order to get an FDA approval for NGS based in vitro diagnostics technique, the expenditure can cost between USD 20 to 30 million thus, the high developmental cost has restricted the commercialization of NGS diagnostic tests. Furthermore, in developing regions individuals are unaware of the advantages of next-generation diagnostics. In addition, developing regions lack the required funds for the procurement of hardware required for the setup of laboratories thus, hampering the development of the market.
Opportunities:
Government Initiatives to Reduce the Cancer Burden
By avoiding risk factors and adapting evidence-based prevention strategies, 30 to 50 % of cancers can be avoided. Early detection, as well as adequate treatment and care for cancer patients, can help in decreasing the cancer burden. Many cancers have a good possibility of being cured if detected early and treated appropriately. Several governments have taken steps to combat the spread of noncommunicable diseases. Noncommunicable diseases, such as cardiovascular disease, cancer, chronic respiratory disease, diabetes, and others, are thought to account for over 60% of all deaths in India.
The National Programme for the Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) was started in 2010 with an emphasis on infrastructure, human resource development, health promotion, early diagnosis, management, and referral to prevent and control major NCDs. The Government of India has launched the Tertiary Care Cancer Centers (TCCC) initiative, which aims to establish/strengthen 20 State Cancer Institutes (SCI) and 50 TCCCs across the country to provide comprehensive cancer care. A 'one-time grant' of USD 15 million for each SCI and USD 6 million per TCCC is provided under the scheme, to be used for building construction and equipment procurement. Similar initiatives by other governments are expected to create opportunities for market players.
Segmentation Analysis Of Next Generation Gynecological Cancer Diagnostic Market
By technology, the Next Generation Sequencing segment is anticipated to develop at the highest CAGR over the forecasted timeframe. Next-Generation Sequencing has proven to be a valuable tool for obtaining a deeper and more precise look into the molecular underpinnings of individual tumors. When compared to traditional approaches, NGS has the potential to have a significant impact on the field of oncology due to its accuracy, sensitivity, and speed. Since NGS can test numerous genes in a single assay, it eliminates the need for multiple tests to find the causative mutation thus, supporting the development of the segment.
By function, the companion diagnostics segment is anticipated to dominate the next-generation gynecological cancer diagnostic market over the forecasted timeframe. Companion diagnostics assist healthcare professionals in determining a patient's response to a specific agent to improve cancer patient outcomes and improve personalized medicine. This also aids in the reduction of rising healthcare expenses by limiting drug use to only those who will significantly benefit from it thus, strengthening the expansion of the segment in the projected period.
By application, the biomarker development segment is expected to lead the development of the next-generation gynecological cancer diagnostic market. Patients with the same cancer type used to get the same treatment, but research has shown that tumors, even within the same cancer type, have distinct characteristics. Physicians are increasingly relying on cancer biomarkers to learn more about a patient's tumor and predict which treatment will be most effective against their specific cancer. Biomarkers can be utilized to personalize therapy for individual patients, reducing treatment costs.
Regional Analysis Of Next Generation Gynecological Cancer Diagnostic Market
The North American region is anticipated to dominate the next-generation cancer diagnostics market over the forecasted period attributed to the growing prevalence of ovarian cancer. According to the American Cancer Society, about 19,880 women in the United States will receive a new diagnosis of ovarian cancer in 2022. The Society also estimated that 12,810 women will die from ovarian cancer. Ovarian cancer is the sixth leading cause of cancer death in women, accounting for more fatalities than any other cancer of the female reproductive system. A woman's lifetime risk of developing ovarian cancer is roughly 1 in 78. Her lifetime chance of dying from ovarian cancer is approximately 1 in 108. This cancer primarily affects older women. About half of the women diagnosed with ovarian cancer are 63 or older. The increasing geriatric population coupled with the rise in the number of gynecologic cancer cases are the main factors supporting the development of the market in this region.
The European region is expected to have the second-highest share of the next-generation cancer diagnostics market in the analysis period. Cervical cancer is predicted to account for 2.5 % of cancer cases (excluding non-melanoma skin cancers) identified in women in 2020, and 2.4 % of all cancer deaths in women. Cervical cancer is the 11th most common cancer in women and the 12th most common cause of cancer death in them. In 2020, estimated cervical cancer incidence rates differed fivefold and fatality rates eightfold throughout the EU-27. This wide range can be attributed to differences in HPV prevalence, vaccination, and cervical cancer screening strategies between EU countries. The presence of prominent key players and rise in the R&D activities to develop innovative gynecological cancer diagnostic procedures are expected to support the growth of the market in this region.
The next-generation cancer diagnostics market in the Asia-Pacific region is anticipated to develop at the highest CAGR over the analysis period. According to ICO/IARC Information Centre on HPV and Cancer, every year 123,907 women in India are diagnosed with cervical cancer, and 77,348 die from the disease. Cervical cancer is the second most common disease among women in India, and the second most common cancer among women aged 15 to 44. Moreover, the growing prevalence of ovarian, uterine, vaginal, and vulvar cancer cases in Japan, China, Indonesia, Singapore, and South Korea is expected to propel the growth of the next-generation cancer diagnostics market in this region.
COVID 19 Impacts On Next Generation Gynecological Cancer Diagnostic Market
The COVID-19 pandemic significantly affected cancer diagnostics procedures. Innovative diagnostics procedures that were under trial were halted to curb the spread of the novel coronavirus. According to a Lancet study, cancer services in India, such as new patient registrations, outpatient treatments, hospital admissions, and major surgeries, decreased between March and May 2020, compared to the same period in 2019. It was discovered that these interruptions might result in 83,600-111,500 people seeking cancer care for more advanced conditions during the next two years. Excess cancer-related fatalities in the following five years might range from 98,650 to 131,500, according to the report. To summarize, the R&D activities are expected to increase as the COVID cases decrease attributed to the growing vaccination rate. Market players are expected to launch advanced diagnostics techniques to recuperate from the COVID-19 pandemic.
Top Key Players Covered In Next Generation Gynecological Cancer Diagnostic Market
- Agilent Technologies (California, United States)
- ARUP Laboratories (California, United States)
- BGI Genomics (Shenzhen, China)
- CENTOGENE N.V. (Rostock, Germany)
- F. Hoffmann-La Roche Ltd (Basel, Switzerland)
- Fulgent Genetics (California, United States)
- Illumina Inc. (California, United States)
- Invitae Corporation (California, United States)
- Konica Minolta Inc. (Tokyo, Japan)
- Laboratory Corporation of America Holdings (California, United States)
- Myriad Genetics (Utah, United States)
- OPKO Health Inc. (Florida, United States)
- QIAGEN N.V. (Germany)
- Quest Diagnostics Incorporated (US)
- Thermo Fisher Scientific Inc. (US) and Other Major Players.
Key Industry Developments In The Next Generation Gynecological Cancer Diagnostic Market
- In February 2024, Hologic has received FDA clearance for its AI-enabled Genius Digital Diagnostics System, revolutionizing cervical cancer screening. The system digitizes Pap test slides and employs AI to identify cells for review, allowing cytologists and pathologists to detect potential cancers more efficiently. Hologic claims a study showed a 28% reduction in false negatives for severe lesions compared to traditional methods. Already available in Europe, the system is set to launch in the U.S. this year, giving Hologic a competitive edge over BD, which is still developing its AI-enabled screening technology.
- In September 2024, Ahmedabad-based DNA Wellness Private Limited is investing ā¹200 crore to set up 100 cervical cancer screening labs across India, introducing the advanced DNA Ploidy Test with exclusive rights from Canada's British Columbia Cancer Research Agency. This non-invasive test, offering 100% specificity and 98% sensitivity, can detect cancerous cells two years earlier than traditional methods. The first lab has launched in Ahmedabad, with more planned in Vadodara, Rajkot, and Surat by October 2024. With cervical cancer causing 1.3 lakh cases and 80,000 deaths annually in India, experts highlight the test's potential to revolutionize early detection and save lives.
Next Generation Gynecological Cancer Diagnostic Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 2.67 Bn. |
Forecast Period 2024-32 CAGR: |
10.70 % |
Market Size in 2032: |
USD 6.67 Bn. |
Segments Covered: |
By Technology |
|
|
By Function |
|
||
By Application |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Chapter 1: Introduction
ā1.1 Research Objectives
ā1.2 Research Methodology
ā1.3 Research Process
ā1.4 Scope and Coverage
āā1.4.1 Market Definition
āā1.4.2 Key Questions Answered
ā1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
ā3.1 By Technology
ā3.2 By Function
ā3.3 By Application
Chapter 4: Market Landscape
ā4.1 Porter's Five Forces Analysis
āā4.1.1 Bargaining Power of Supplier
āā4.1.2 Threat of New Entrants
āā4.1.3 Threat of Substitutes
āā4.1.4 Competitive Rivalry
āā4.1.5 Bargaining Power Among Buyers
ā4.2 Industry Value Chain Analysis
ā4.3 Market Dynamics
āā4.3.1 Drivers
āā4.3.2 Restraints
āā4.3.3 Opportunities
āā4.5.4 Challenges
ā4.4 Pestle Analysis
ā4.5 Technological Roadmap
ā4.6 Regulatory Landscape
ā4.7 SWOT Analysis
ā4.8 Price Trend Analysis
ā4.9 Patent Analysis
ā4.10 Analysis of the Impact of Covid-19
āā4.10.1 Impact on the Overall Market
āā4.10.2 Impact on the Supply Chain
āā4.10.3 Impact on the Key Manufacturers
āā4.10.4 Impact on the Pricing
Chapter 5: Next Generation Gynecological Cancer Diagnostic Market by Technology
ā5.1 Next Generation Gynecological Cancer Diagnostic Market Overview Snapshot and Growth Engine
ā5.2 Next Generation Gynecological Cancer Diagnostic Market Overview
ā5.3 qPCR & Multiplexing
āā5.3.1 Introduction and Market Overview
āā5.3.2 Historic and Forecasted Market Size (2017-2032F)
āā5.3.3 Key Market Trends, Growth Factors and Opportunities
āā5.3.4 qPCR & Multiplexing: Grographic Segmentation
ā5.4 Next-Generation Sequencing
āā5.4.1 Introduction and Market Overview
āā5.4.2 Historic and Forecasted Market Size (2017-2032F)
āā5.4.3 Key Market Trends, Growth Factors and Opportunities
āā5.4.4 Next-Generation Sequencing: Grographic Segmentation
ā5.5 LOAC & RT-PCR
āā5.5.1 Introduction and Market Overview
āā5.5.2 Historic and Forecasted Market Size (2017-2032F)
āā5.5.3 Key Market Trends, Growth Factors and Opportunities
āā5.5.4 LOAC & RT-PCR: Grographic Segmentation
ā5.6 Other
āā5.6.1 Introduction and Market Overview
āā5.6.2 Historic and Forecasted Market Size (2017-2032F)
āā5.6.3 Key Market Trends, Growth Factors and Opportunities
āā5.6.4 Other: Grographic Segmentation
Chapter 6: Next Generation Gynecological Cancer Diagnostic Market by Function
ā6.1 Next Generation Gynecological Cancer Diagnostic Market Overview Snapshot and Growth Engine
ā6.2 Next Generation Gynecological Cancer Diagnostic Market Overview
ā6.3 Companion Diagnostics
āā6.3.1 Introduction and Market Overview
āā6.3.2 Historic and Forecasted Market Size (2017-2032F)
āā6.3.3 Key Market Trends, Growth Factors and Opportunities
āā6.3.4 Companion Diagnostics: Grographic Segmentation
ā6.4 Therapeutic & Monitoring
āā6.4.1 Introduction and Market Overview
āā6.4.2 Historic and Forecasted Market Size (2017-2032F)
āā6.4.3 Key Market Trends, Growth Factors and Opportunities
āā6.4.4 Therapeutic & Monitoring: Grographic Segmentation
ā6.5 Prognostic
āā6.5.1 Introduction and Market Overview
āā6.5.2 Historic and Forecasted Market Size (2017-2032F)
āā6.5.3 Key Market Trends, Growth Factors and Opportunities
āā6.5.4 Prognostic: Grographic Segmentation
ā6.6 Cancer
āā6.6.1 Introduction and Market Overview
āā6.6.2 Historic and Forecasted Market Size (2017-2032F)
āā6.6.3 Key Market Trends, Growth Factors and Opportunities
āā6.6.4 Cancer: Grographic Segmentation
ā6.7 Screening
āā6.7.1 Introduction and Market Overview
āā6.7.2 Historic and Forecasted Market Size (2017-2032F)
āā6.7.3 Key Market Trends, Growth Factors and Opportunities
āā6.7.4 Screening: Grographic Segmentation
ā6.8 Risk Analysis
āā6.8.1 Introduction and Market Overview
āā6.8.2 Historic and Forecasted Market Size (2017-2032F)
āā6.8.3 Key Market Trends, Growth Factors and Opportunities
āā6.8.4 Risk Analysis: Grographic Segmentation
Chapter 7: Next Generation Gynecological Cancer Diagnostic Market by Application
ā7.1 Next Generation Gynecological Cancer Diagnostic Market Overview Snapshot and Growth Engine
ā7.2 Next Generation Gynecological Cancer Diagnostic Market Overview
ā7.3 Biomarker Development
āā7.3.1 Introduction and Market Overview
āā7.3.2 Historic and Forecasted Market Size (2017-2032F)
āā7.3.3 Key Market Trends, Growth Factors and Opportunities
āā7.3.4 Biomarker Development: Grographic Segmentation
ā7.4 CTC Analysis
āā7.4.1 Introduction and Market Overview
āā7.4.2 Historic and Forecasted Market Size (2017-2032F)
āā7.4.3 Key Market Trends, Growth Factors and Opportunities
āā7.4.4 CTC Analysis: Grographic Segmentation
ā7.5 Proteomic Analysis
āā7.5.1 Introduction and Market Overview
āā7.5.2 Historic and Forecasted Market Size (2017-2032F)
āā7.5.3 Key Market Trends, Growth Factors and Opportunities
āā7.5.4 Proteomic Analysis: Grographic Segmentation
ā7.6 Epigenetic Analysis
āā7.6.1 Introduction and Market Overview
āā7.6.2 Historic and Forecasted Market Size (2017-2032F)
āā7.6.3 Key Market Trends, Growth Factors and Opportunities
āā7.6.4 Epigenetic Analysis: Grographic Segmentation
ā7.7 Others
āā7.7.1 Introduction and Market Overview
āā7.7.2 Historic and Forecasted Market Size (2017-2032F)
āā7.7.3 Key Market Trends, Growth Factors and Opportunities
āā7.7.4 Others: Grographic Segmentation
Chapter 8: Company Profiles and Competitive Analysis
ā8.1 Competitive Landscape
āā8.1.1 Competitive Positioning
āā8.1.2 Next Generation Gynecological Cancer Diagnostic Sales and Market Share By Players
āā8.1.3 Industry BCG Matrix
āā8.1.4 Ansoff Matrix
āā8.1.5 Next Generation Gynecological Cancer Diagnostic Industry Concentration Ratio (CR5 and HHI)
āā8.1.6 Top 5 Next Generation Gynecological Cancer Diagnostic Players Market Share
āā8.1.7 Mergers and Acquisitions
āā8.1.8 Business Strategies By Top Players
ā8.2 AGILENT TECHNOLOGIES
āā8.2.1 Company Overview
āā8.2.2 Key Executives
āā8.2.3 Company Snapshot
āā8.2.4 Operating Business Segments
āā8.2.5 Product Portfolio
āā8.2.6 Business Performance
āā8.2.7 Key Strategic Moves and Recent Developments
āā8.2.8 SWOT Analysis
ā8.3 ARUP LABORATORIES
ā8.4 BGI GENOMICS
ā8.5 CENTOGENE N.V.
ā8.6 F. HOFFMANN-LA ROCHE LTD
ā8.7 FULGENT GENETICS
ā8.8 ILLUMINA INC
ā8.9 INVITAE CORPORATION
ā8.10 KONICA MINOLTA INC.
ā8.11 LABORATORY CORPORATION OF AMERICA HOLDINGS
ā8.12 MYRIAD GENETICS
ā8.13 OPKO HEALTH INC.
ā8.14 QIAGEN N.V.
ā8.15 QUEST DIAGNOSTICS INCORPORATED
ā8.16 THERMO FISHER SCIENTIFIC INC
ā8.17 OTHER MAJOR PLAYERS
Chapter 9: Global Next Generation Gynecological Cancer Diagnostic Market Analysis, Insights and Forecast, 2017-2032
ā9.1 Market Overview
ā9.2 Historic and Forecasted Market Size By Technology
āā9.2.1 qPCR & Multiplexing
āā9.2.2 Next-Generation Sequencing
āā9.2.3 LOAC & RT-PCR
āā9.2.4 Other
ā9.3 Historic and Forecasted Market Size By Function
āā9.3.1 Companion Diagnostics
āā9.3.2 Therapeutic & Monitoring
āā9.3.3 Prognostic
āā9.3.4 Cancer
āā9.3.5 Screening
āā9.3.6 Risk Analysis
ā9.4 Historic and Forecasted Market Size By Application
āā9.4.1 Biomarker Development
āā9.4.2 CTC Analysis
āā9.4.3 Proteomic Analysis
āā9.4.4 Epigenetic Analysis
āā9.4.5 Others
Chapter 10: North America Next Generation Gynecological Cancer Diagnostic Market Analysis, Insights and Forecast, 2017-2032
ā10.1 Key Market Trends, Growth Factors and Opportunities
ā10.2 Impact of Covid-19
ā10.3 Key Players
ā10.4 Key Market Trends, Growth Factors and Opportunities
ā10.4 Historic and Forecasted Market Size By Technology
āā10.4.1 qPCR & Multiplexing
āā10.4.2 Next-Generation Sequencing
āā10.4.3 LOAC & RT-PCR
āā10.4.4 Other
ā10.5 Historic and Forecasted Market Size By Function
āā10.5.1 Companion Diagnostics
āā10.5.2 Therapeutic & Monitoring
āā10.5.3 Prognostic
āā10.5.4 Cancer
āā10.5.5 Screening
āā10.5.6 Risk Analysis
ā10.6 Historic and Forecasted Market Size By Application
āā10.6.1 Biomarker Development
āā10.6.2 CTC Analysis
āā10.6.3 Proteomic Analysis
āā10.6.4 Epigenetic Analysis
āā10.6.5 Others
ā10.7 Historic and Forecast Market Size by Country
āā10.7.1 U.S.
āā10.7.2 Canada
āā10.7.3 Mexico
Chapter 11: Europe Next Generation Gynecological Cancer Diagnostic Market Analysis, Insights and Forecast, 2017-2032
ā11.1 Key Market Trends, Growth Factors and Opportunities
ā11.2 Impact of Covid-19
ā11.3 Key Players
ā11.4 Key Market Trends, Growth Factors and Opportunities
ā11.4 Historic and Forecasted Market Size By Technology
āā11.4.1 qPCR & Multiplexing
āā11.4.2 Next-Generation Sequencing
āā11.4.3 LOAC & RT-PCR
āā11.4.4 Other
ā11.5 Historic and Forecasted Market Size By Function
āā11.5.1 Companion Diagnostics
āā11.5.2 Therapeutic & Monitoring
āā11.5.3 Prognostic
āā11.5.4 Cancer
āā11.5.5 Screening
āā11.5.6 Risk Analysis
ā11.6 Historic and Forecasted Market Size By Application
āā11.6.1 Biomarker Development
āā11.6.2 CTC Analysis
āā11.6.3 Proteomic Analysis
āā11.6.4 Epigenetic Analysis
āā11.6.5 Others
ā11.7 Historic and Forecast Market Size by Country
āā11.7.1 Germany
āā11.7.2 U.K.
āā11.7.3 France
āā11.7.4 Italy
āā11.7.5 Russia
āā11.7.6 Spain
āā11.7.7 Rest of Europe
Chapter 12: Asia-Pacific Next Generation Gynecological Cancer Diagnostic Market Analysis, Insights and Forecast, 2017-2032
ā12.1 Key Market Trends, Growth Factors and Opportunities
ā12.2 Impact of Covid-19
ā12.3 Key Players
ā12.4 Key Market Trends, Growth Factors and Opportunities
ā12.4 Historic and Forecasted Market Size By Technology
āā12.4.1 qPCR & Multiplexing
āā12.4.2 Next-Generation Sequencing
āā12.4.3 LOAC & RT-PCR
āā12.4.4 Other
ā12.5 Historic and Forecasted Market Size By Function
āā12.5.1 Companion Diagnostics
āā12.5.2 Therapeutic & Monitoring
āā12.5.3 Prognostic
āā12.5.4 Cancer
āā12.5.5 Screening
āā12.5.6 Risk Analysis
ā12.6 Historic and Forecasted Market Size By Application
āā12.6.1 Biomarker Development
āā12.6.2 CTC Analysis
āā12.6.3 Proteomic Analysis
āā12.6.4 Epigenetic Analysis
āā12.6.5 Others
ā12.7 Historic and Forecast Market Size by Country
āā12.7.1 China
āā12.7.2 India
āā12.7.3 Japan
āā12.7.4 Singapore
āā12.7.5 Australia
āā12.7.6 New Zealand
āā12.7.7 Rest of APAC
Chapter 13: Middle East & Africa Next Generation Gynecological Cancer Diagnostic Market Analysis, Insights and Forecast, 2017-2032
ā13.1 Key Market Trends, Growth Factors and Opportunities
ā13.2 Impact of Covid-19
ā13.3 Key Players
ā13.4 Key Market Trends, Growth Factors and Opportunities
ā13.4 Historic and Forecasted Market Size By Technology
āā13.4.1 qPCR & Multiplexing
āā13.4.2 Next-Generation Sequencing
āā13.4.3 LOAC & RT-PCR
āā13.4.4 Other
ā13.5 Historic and Forecasted Market Size By Function
āā13.5.1 Companion Diagnostics
āā13.5.2 Therapeutic & Monitoring
āā13.5.3 Prognostic
āā13.5.4 Cancer
āā13.5.5 Screening
āā13.5.6 Risk Analysis
ā13.6 Historic and Forecasted Market Size By Application
āā13.6.1 Biomarker Development
āā13.6.2 CTC Analysis
āā13.6.3 Proteomic Analysis
āā13.6.4 Epigenetic Analysis
āā13.6.5 Others
ā13.7 Historic and Forecast Market Size by Country
āā13.7.1 Turkey
āā13.7.2 Saudi Arabia
āā13.7.3 Iran
āā13.7.4 UAE
āā13.7.5 Africa
āā13.7.6 Rest of MEA
Chapter 14: South America Next Generation Gynecological Cancer Diagnostic Market Analysis, Insights and Forecast, 2017-2032
ā14.1 Key Market Trends, Growth Factors and Opportunities
ā14.2 Impact of Covid-19
ā14.3 Key Players
ā14.4 Key Market Trends, Growth Factors and Opportunities
ā14.4 Historic and Forecasted Market Size By Technology
āā14.4.1 qPCR & Multiplexing
āā14.4.2 Next-Generation Sequencing
āā14.4.3 LOAC & RT-PCR
āā14.4.4 Other
ā14.5 Historic and Forecasted Market Size By Function
āā14.5.1 Companion Diagnostics
āā14.5.2 Therapeutic & Monitoring
āā14.5.3 Prognostic
āā14.5.4 Cancer
āā14.5.5 Screening
āā14.5.6 Risk Analysis
ā14.6 Historic and Forecasted Market Size By Application
āā14.6.1 Biomarker Development
āā14.6.2 CTC Analysis
āā14.6.3 Proteomic Analysis
āā14.6.4 Epigenetic Analysis
āā14.6.5 Others
ā14.7 Historic and Forecast Market Size by Country
āā14.7.1 Brazil
āā14.7.2 Argentina
āā14.7.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Next Generation Gynecological Cancer Diagnostic Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 2.67 Bn. |
Forecast Period 2024-32 CAGR: |
10.70 % |
Market Size in 2032: |
USD 6.67 Bn. |
Segments Covered: |
By Technology |
|
|
By Function |
|
||
By Application |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Frequently Asked Questions :
The forecast period in the Next Generation Gynecological Cancer Diagnostic Market research report is 2024-2032.
Agilent Technologies (California, United States), ARUP Laboratories (California, United States), BGI Genomics (Shenzhen, China), CENTOGENE N.V. (Rostock, Germany), F. Hoffmann-La Roche Ltd (Basel, Switzerland), Fulgent Genetics (California, United States), Illumina Inc. (California, United States), Invitae Corporation (California, United States), Konica Minolta Inc. (Tokyo, Japan), Laboratory Corporation of America Holdings (California, United States), Myriad Genetics (Utah, United States), OPKO Health Inc. (Florida, United States), QIAGEN N.V. (Germany), Quest Diagnostics Incorporated (US), Thermo Fisher Scientific Inc. (US), and Other Major Players.
Next Generation Gynecological Cancer Diagnostic Market is segmented into Technology, Function, Application and region. By Technology, the market is categorized into qPCR & Multiplexing, Next-Generation Sequencing, LOAC & RT-PCR, Other. By Function, the market is categorized into Companion Diagnostics, Therapeutic & Monitoring, Prognostic, Cancer Screening, and Risk Analysis. By Application, the market is categorized into Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Others. By region, it is analysed across North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain, etc.), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
Cancer that originates in a woman's reproductive organs is referred to as gynaecologic cancer. Cancer is always named after the body part where it first appears. Advancement in technology has resulted in the development of innovative techniques for the diagnosis of gynecologic cancer such as quantitative polymerase chain reaction (qPCR) & multiplexing, next-generation sequencing, and lab-on-a-chip (LOAC) & reverse transcription-polymerase chain reaction (RT-PCR), and microarray.
The Global Next Generation Gynecological Cancer Diagnostic Market size is expected to grow from USD 2.67 billion in 2023 to USD 6.67 billion by 2032, at a CAGR of 10.70% during the forecast period (2024-2032).